Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Novamind

Psychedelics Companies Share Corporate Updates: Numinus, Delix, Tryp And Small Pharma

Numinus Updates On New Acquisition’s Integration And Provides Client Financing Options

Benzinga · Sep 14, 2022

World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them

The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business landscape.

Benzinga · Aug 30, 2022

Numinus Wellness Announces Q3 Results

Mental healthcare company advancing psychedelic-assisted therapies Numinus Wellness Inc. (OTCQX: NUMIF) recently announced its fiscal quarter results for the three and nine months ended May 31, 2022.

Benzinga · Jul 15, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill

Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider.

Benzinga · Jun 15, 2022

New Acquisition: Numinus To Buy Common Shares Of Novamind Pending Canadian Supreme Court Approval

Numinus Wellness Inc.

Benzinga · Jun 9, 2022

Novamind And Numinus Prepare For Acquisition, Both Companies Share Info Circulars To Shareholders

June 8, 2022 marks a turning point for both Numinus (OTCQX: NUMIF) and Novamind (OTCQB: NVMDF).

Benzinga · May 11, 2022

Psyched: Elon Musk Praises Psychedelics Over Antidepressants, Field Trip To Split In Two, Colorado MDMA Bill Moves Forward

The world’s richest man gave another public nod to psychedelics medicine in favor of traditional mental health solutions.

Benzinga · May 2, 2022

Read news from The Economist, FT, and more,
with one subscription

Novamind To Offer Virtual Mental Health Therapy Sessions

Novamind (OTCQB: NVMDF), which is to be acquired by Numinus Wellness (OTCMKTS: NUMIF), recently announced a collaboration with health coaching platform HealCommunit

Benzinga · May 2, 2022

Numinus Wellness Strives To Become Psychedelic Research Hub After Acquisition Of Novamind Inc.

In a year where M&A activity is expected to ratchet-up in 2022, Numinus Wellness Inc. (OTC: NUMIF) is among the first to take action.

Benzinga · Apr 13, 2022

Numinus To Acquire Novamind For $20.74M In Stock

Numinus Wellness Inc. (TSX:NUMI)(OTCQX:NUMIF) and Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) have entered into a definitive arrangement agreement pursuant to which Numinus will acquire all of the issued and outstanding common shares of Novamind in an all-share transaction, by way of a court-approved plan of arrangement, for total consideration of approximately CA$26.2 million…

Benzinga · Apr 12, 2022

Core One Labs Begins Trading On OTCQB

Under the CLABF symbol, psychedelics-oriented company Core One Labs (OTCQB:CLABF) started trading on the OTCQB Venture Market. The company’s CEO, Joel Shacker, commented: “Upgrading to the OTCQB is a timely and important milestone for Core One, as it will not only lead to increased corporate visibility in the US marketplace,…

Benzinga · Apr 6, 2022

Psyched: Third Michigan City Decriminalizes Psychedelics, MindMed Reports $133M Cash Position, Real Brands To Enter The Space

The psychedelics legislative landscape continues to move forward with Hazel Park, Michigan enacting decriminalization measures for naturally-produced psychedelic molecules, becoming the third city in the state to do so after Ann Arbor and Detroit. In Utah, Governor Cox signed a psychedelics research bill into law and positive legislation around psilocybin is continuing…

Benzinga · Mar 29, 2022

Novamind To Offer Psychedelic-Assisted Group Therapy

Novamind Inc. (OTCQB:NVMDF) has announced that it will offer a model of psychedelic-assisted group therapy. Under the name Groups by Novamind, the therapy model will offer psychedelic integration and in-person group psychedelic-assisted psychotherapy for four to ten individuals delivered as drop-in sessions or multi-week curricula. According to the company, the…

Benzinga · Mar 24, 2022

Psyched: MindCure Shuts Down Operations, Novamind And MindMed Partner For Study

The psychedelics space was shaken up on the news that MindCure Health (OTC:MCURF) was shutting down operations. After a review process, the company’s board decided that MindCure’s business plan required more capital that it could gather under current market conditions, thus shutting down operations was considered the best move to preserve…

Benzinga · Mar 22, 2022

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Mar 16, 2022

Novamind To Host MindMed Phase IIb Trial For LSD Based Drug For Anxiety Treatment

Novamind Inc. (OTCQB:NVMDF) (CSE:NM) (FSE:HN2) has been selected by Mind Medicine, Inc. (NASDAQ:MNMD) (NEO:MMED) to host a Phase IIb randomized clinical trial investigating lysergic acid diethylamide (LSD) for generalized anxiety disorder in adults.

Benzinga · Mar 15, 2022

Psyched: Albert Labs Goes Public, Ex-Moderna Executive Joins MAPS, Novamind and Usona Join For Phase 2 Psilocybin Trial

A new company has entered the public psychedelic markets, with an alternative drug-to-market approach. Using Real World Evidence trials, Albert Labs is expecting to legally provide psilocybin to patients in the UK much earlier than companies working with to get FDA approval.

Benzinga · Mar 11, 2022

Novamind Stock Slightly Up On Grants Restricted Share Units

Novamind Inc. (OTCQB:NVMDF)(CSE:NM)(FSE:HN2) a mental health company specialized in psychedelic medicine, has granted an aggregate of 325,000 restricted share units effective March 11, 2022, to certain executives and employees of the company pursuant to its restricted share unit plan. The RSUs will vest in 25% intervals, every 6 months from…

Benzinga · Mar 9, 2022

Novamind To Conduct Phase II Psilocybin Trial For Major Depressive Disorder

Novamind Inc. (OTCQB:NVMDF) (CSE:NM)(FSE:HN2) will conduct a phase II clinical trial investigating psilocybin for major depressive disorder sponsored by the Usona Institute. The company completed first patient randomization at its Draper, Utah research site.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Mar 7, 2022

Psyched: First Australian Psych Company On Nasdaq, Utah's Psychedelics Bill, LSD Vs. Psilocybin Study Unprecedented Results

On the legislative front of the psychedelics space, a new bill meant to study the therapeutic effects of psychedelic substances received full approval in both Utah chambers, standing out from among dozens of measures currently circulating in legislatures across several U.S. states. Psychedelic science also took an important step forward with the publication…

Benzinga · Mar 2, 2022

Novamind Posts Record High Revenue Of CA$2.45M, Up 32% QoQ

Psychedelics-focused mental health company Novamind Inc. (CSE:NM) (OTCQB: NVMDF) (FSE: HN2) reported its financial results for the three and six months ended December 31, 2021.

Benzinga · Feb 3, 2022

Novamind To Host Clinical Trial To Advance Ketamine Therapy For End-of-Life Patients

Mental health company specialized in psychedelic medicine Novamind Inc. (CSE:NM) (OTCQB: NVMDF) (FSE:HN2) has been selected by the Ketamine Research Foundation to host a phase II clinical trial investigating ketamine-assisted psychotherapy (KAP) for adults with life-threatening illness.

Benzinga · Jan 24, 2022

Novamind Stock Dives On $3.95M Private Placement With Institutional Investor

Novamind Inc. (CSE: NM) (OTCQB: NVMDF) (FSE: HN2) announced Monday a CA$5 million ($3.95 million) private placement with an institutional investor.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Johns Hopkins University

Psychedelic Spotlight

29 stories

Cerebral

25 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.